Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15525347 | 1.00 | PNP (0.35) | PNP | |
| SCHEMBL25719173 | 1.00 | PNP (0.35) | PNP | |
| SCHEMBL15718943 | 0.81 | PNP (0.38) | PNP | |
| SCHEMBL15718942 | 0.81 | PNP (0.38) | PNP | |
| SCHEMBL15525795 | 0.80 | PNP (0.32) | PNP | |
| SCHEMBL15525797 | 0.80 | PNP (0.32) | PNP | |
| SCHEMBL18558183 | 0.80 | PNP (0.32) | PNP | |
| SCHEMBL15740163 | 0.79 | — | — | |
| SCHEMBL15740270 | 0.79 | — | — | |
| SCHEMBL16257613 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170128454-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-9580428-B2 | Compositions and methods for inhibiting viral polymerase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580428-B2 | Compositions and methods for inhibiting viral polymerase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150191472-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| EP-2838535-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | Biocryst Pharmaceuticals, Inc. (US) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013158746-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128454-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | POLRMT, POLR1E, POLR1A | PNP 71/4885 |
| US-20150191472-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | POLRMT, POLR1E, POLR1A | PNP 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.